Harmony Garges, M.D, senior vice president, chief medical officer and head of global medical at ViiV Healthcare, highlighted ...

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...

ViiV Healthcare, the specialist HIV company majority owned by GSK (LSE: GSK), today announced the presentation of new ...

The survey also found that flexible and virtual appointments, as well as transportation support, were helpful while on ...

Cabotegravir – given the trade name Apretude – can be dosed just six times a year and showed superior results to daily, oral therapy with Gilead's widely used Truvada (emtricitabine and ...

Real-world evidence show that GSK and ViiV Healthcare’s long-acting pre-exposure prophylaxis Apretude can prevent nearly all HIV infections, while rival Gilead Sciences is moving quickly toward an ...

The announcement marks another important milestone in our efforts to accelerate access to the only long-acting PrEP available ...

ViiV Healthcare sponsored events to address the climbing rates of HIV infections on HBCU campuses and the surrounding Black ...

At least 2 million doses of Apretude will be made available to meet growing demand where unmet need is greatest.

How Was It Studied for the Prevention of HIV? Two large studies were conducted to see if Apretude is safe and effective as a PrEP regimen in people at risk of getting HIV. In both studies ...

Harmony P. Garges, M.D., MPH, Chief Medical Officer at ViiV Healthcare, said: “The findings presented at IDWeek 2024 continue to support the strong and sustained effectiveness of Apretude for people ...